Try our beta test site
21 studies found for:    Open Studies | GVHD | Phase 3
Show Display Options
Rank Status Study
1 Recruiting Safety Follow-up of Treatment With Remestemcel-L in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Condition: Grades B-D Acute Graft Versus Host Disease
Intervention:
2 Recruiting Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Condition: Graft vs Host Disease
Interventions: Biological: Begelomab;   Biological: Conventional Second-line Treatment
3 Recruiting Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells
Condition: Chronic Graft-Versus-Host Disease
Intervention: Biological: Mesenchymal Stromal Cells
4 Recruiting Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD)
Condition: Chronic Graft Versus Host Disease
Interventions: Drug: ibrutinib;   Drug: Placebo;   Drug: Prednisone
5 Recruiting Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Condition: Corticosteroid Refractory Acute Graft vs Host Disease
Interventions: Drug: Ruxolitinib;   Drug: Best Available Therapy (BAT)
6 Recruiting UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease
Condition: Steroid Refractory Acute Graft Versus Host Disease
Intervention: Drug: UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System
7 Not yet recruiting The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome
Conditions: Graft vs Host Disease;   Allogeneic Hematopoietic Cell Transplantation;   Mucositis
Interventions: Drug: Folinic acid;   Drug: Placebo
8 Recruiting A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD
Condition: Graft Versus Host Disease
Interventions: Biological: GLASSIA;   Drug: methylprednisolone or equivalent steroid;   Biological: Albumin
9 Recruiting Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression
Condition: Graft Versus Host Disease
Intervention: Drug: Tacrolimus and MMF.
10 Recruiting Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
Conditions: Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome
Interventions: Drug: Atorvastatin;   Drug: Methotrexate;   Drug: Tacrolimus
11 Not yet recruiting Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant
Conditions: Childhood Malignant Neoplasm;   Hematopoietic Cell Transplantation Recipient
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Lactobacillus plantarum strain 299;   Drug: Lactobacillus plantarum strain 299v;   Other: Placebo
12 Recruiting Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
Conditions: Acute Leukemia;   Myelodysplasia
Interventions: Procedure: Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate;   Procedure: Mobilized CD34-selected Peripheral Blood Stem Cell graft;   Procedure: Unmanipulated Bone Marrow Graft with Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Methotrexate
13 Recruiting MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD
Condition: Acute Graft-versus-host Disease
Interventions: Drug: CD25 monoclonal antibody;   Drug: calcineurin inhibitors;   Biological: MSCs
14 Recruiting A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Condition: Grades B-D aGVHD
Intervention: Drug: remestemcel-L
15 Recruiting Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
Conditions: Chronic Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Biphenotypic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Hodgkins Disease;   Chronic Lymphocytic Leukemia;   Multiple Myeloma
Interventions: Drug: tacrolimus;   Drug: methotrexate;   Drug: Mycophenolate mofetil;   Drug: Methotrexate (low dose)
16 Recruiting Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD
Condition: Chronic Graft-versus-host Disease
Intervention: Drug: Hydrogen
17 Recruiting Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Idarubicin;   Drug: Daunorubicin;   Drug: Cytarabine;   Drug: Cyclosporine;   Drug: Methotrexate;   Drug: Mycophenolic acid (MPA)
18 Recruiting CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
Conditions: Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   GvHD;   Opportunistic Infections;   Graft-versus-Host Disease
Intervention: Biological: CD45RA-depleted peripheral blood mononuclear cells
19 Not yet recruiting Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome
Interventions: Biological: ATIR101;   Drug: Cyclophosphamide;   Procedure: T-cell depleted HSCT from a related, haploidentical donor;   Procedure: T-cell replete HSCT from a related, haploidentical donor
20 Recruiting TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
Condition: Acute Leukemia (Category)
Interventions: Genetic: HSV-Tk;   Other: T-cell depleted or T-cell replete strategies

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.